Please assess the completion status of the following clinical trial:

Trial Title: XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects with advanced histologically confirmed biliary cancer (gallbladder cancer or cholangiocarcinoma) that is not amenable to conventional surgical approach~* 18 years or older~* Life expectancy of at least 12 weeks~* Eastern Cooperative Oncology Group (ECOG) Performance Status score less than 3~* Willing and able to sign informed consent~* Sexually active men and women must use an accepted and effective method of contraception (including barrier contraception with spermicide)~* Women of child-bearing age must have a negative pregnancy test~* Laboratory criteria~Exclusion Criteria:~* Prior chemotherapy (excluding chemotherapy given as adjuvant treatment completing more than 6 months prior to entry into study)~* Unstable angina, or class III or IV New York Heart Association heart disease~* Central nervous system metastases~* Uncontrolled diabetes mellitus~* Uncontrolled seizure disorder~* Major surgery, chemotherapy, immunotherapy, or radiotherapy during the 28 days preceding the first study treatment~* Need for concomitant anticancer therapy (chemotherapy, immunotherapy, or radiation) or other investigational agents during study participation or 28 days prior to study participation~* Pregnant or breast-feeding~* A known history of human immunodeficiency virus (HIV) infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- becatecarin (Type: EXPERIMENTAL): becatecarin
- 5-FU Plus Leucovorin (LV) (Type: ACTIVE_COMPARATOR): 5-Fluorouracil (5-FU) Plus Leucovorin (LV)

Based on this trial design, predict the completion outcome and termination type (if applicable).